Klinische Wirksamkeit von gynokadin^® Dosiergel

Naunton, M., et al. (2006, May-Jun). Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause, 13(3), pp. 517-27.

Archer, D., & Group, E. S. (2003, Nov-Dec). Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause, 10(6), pp. 516-21.

Dupont A, et al. (1991). Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas;13(4):297-311.

Devogelaer, J., et al. (1998, Jan). Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women. Maturitas, 28(3), pp. 243-9.

Ribot, C. (1991). Effect of percutaneous estradiol administration on post-menopausal vertebral bone loss. Unpublished Study Report. Laboratoires Besins-Iscovesco.

Ribot, C. et al. (1990). Traitement hormonale et prévention de l’ostéoporose postménopausique: comparaison de l’efficacité des voies percutanée et transdermique. Rev Fr Endocrinol Clin, 31, pp. 261-8.

Palacios, S., Menéndez, C., Jurado, A., & Vargas, J. (1994, Dec). Effects of percutaneous estradiol versus oral estrogens on bone density. Maturitas, 20(2-3), pp. 209-13.

Wimalawansa, S. (1995, Jul). Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four year randomized study. Am J Med, 99(1), pp. 36-42.